Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study of the Safety and Efficacy of LX2020 Gene Therapy in Patients With Arrhythmogenic Cardiomyopathy Due to a Plakophilin-2 Pathogenic Variant

Next Previous
Trial Profile

A Phase 1/2 Study of the Safety and Efficacy of LX2020 Gene Therapy in Patients With Arrhythmogenic Cardiomyopathy Due to a Plakophilin-2 Pathogenic Variant

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs LX-2020 (Primary)
  • Indications Cardiomyopathies
  • Focus Adverse reactions; First in man
  • Acronyms HEROIC-PKP2
  • Sponsors LEXEO Therapeutics

Most Recent Events

  • 24 Mar 2025 According to a LEXEO Therapeutics media release, the company has completed the enrollment in Cohort-2 of this study with interim clinical data update expected in 2H 2025. the company has also released interim update from cohort 1 of this trial where 1st participant evaluated 6-months after dosing experienced 67% reduction in premature ventricular contractions (PVCs).
  • 13 Nov 2024 According to a LEXEO Therapeutics media release, completed enrollment of cohort 1 of LX2020 HEROIC-PKP2 Phase 1/2 trial; initial clinical data including safety and biodistribution on track for late Q1 / early Q2 2025
  • 08 Mar 2024 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top